Literature DB >> 7430504

Dose-response studies of the suppression of whole blood histamine and basophil counts by prednisone.

A M Saavedra-Delgado, K P Mathews, P M Pan, D R Kay, M L Muilenberg.   

Abstract

If some clinical problems (e.g., radiographic contrast media reactions) arise from mediator release by circulating basophils, prednisone's capacity to prevent such is likely to be at least partly related to its suppressive effects on whole blood histamine and basophil levels. To establish an optimal dosage schedule, 15 healthy male volunteers entered a two-phased study to determine (1) the single dose of prednisone required to produce maximal suppression of histamine and basophil levels and (2) the effects of repeated prednisone doses. Parameters monitored were whole blood histamine, quantitative basophil counts, white blood cell (WBC) and differential counts, and plasma prednisone, prednisolone, and cortisol levels. Fifty milligrams prednisone suppressed whole blood histamine levels as much as a larger dose and also showed a marked effect on circulating basophils and other leukocytes. Three 50-mg prednisone doses given at 6-hr intervals had a greater effect on whole blood histamine and circulating leukocytes than fewer doses. Thus, the commonly used empirical prednisone dosage regimen is supported. One implication of the results of this study is that greater suppression of blood basophils and histamine levels might be obtained by administering the last prednisone dose about 6 hr before procedures in which a very rapid release of mediators from basophils is anticipated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430504     DOI: 10.1016/0091-6749(80)90007-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  15 in total

1.  Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat.

Authors:  G M Meno-Tetang; Y Y Hon; S Van Wart; W J Jusko
Journal:  Drug Metabol Drug Interact       Date:  1999

Review 2.  Anaphylactic and anaphylactoid reactions due to anesthetic agents.

Authors:  M Schatz; D L Fung
Journal:  Clin Rev Allergy       Date:  1986-05

3.  Assessment of the systemic effects of inhaled glucocorticosteroids: the influence of blood sampling technique and frequency on plasma cortisol and leucocytes.

Authors:  B H Jennings; K E Andersson; S A Johansson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics.

Authors:  J A Wald; D E Salazar; H Y Chen; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

5.  Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism.

Authors:  Yuen Yi Hon; William J Jusko; Vicky E Spratlin; Michael W Jann
Journal:  J Clin Pharmacol       Date:  2006-04       Impact factor: 3.126

6.  Blood histamine and solid malignant tumors.

Authors:  C M Moriarty; J L Stucky; K W Hamburger; K D Patil; J F Foley; R R Koefoot
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  Low level of circulating basophil counts in biopsy-proven active lupus nephritis.

Authors:  Peifen Liang; Ying Tang; Liu Lin; Haowen Zhong; Hui Yang; Yuchun Zeng; Jun Lv; Xiaomei Li; Yanying Lu; Anping Xu
Journal:  Clin Rheumatol       Date:  2017-10-08       Impact factor: 2.980

8.  Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.

Authors:  A N Kong; E A Ludwig; R L Slaughter; P M DiStefano; J DeMasi; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1989-12       Impact factor: 6.875

9.  Receptor-mediated pharmacodynamics of prednisolone in the rat.

Authors:  F D Boudinot; R D'Ambrosio; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

Review 10.  Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.